Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - X4 Pharmaceuticals, Inc | ex-322q42020.htm |
| EX-32.1 - EX-32.1 - X4 Pharmaceuticals, Inc | ex-321q42020.htm |
| EX-31.2 - EX-31.2 - X4 Pharmaceuticals, Inc | ex-312q42020.htm |
| EX-31.1 - EX-31.1 - X4 Pharmaceuticals, Inc | ex-311q42020.htm |
| EX-21.1 - EX-21.1 - X4 Pharmaceuticals, Inc | ex_211xlistofsubsidiaries2.htm |
| EX-10.48 - EX-10.48 - X4 Pharmaceuticals, Inc | aptuitamendment2.htm |
| EX-10.33 - EX-10.33 - X4 Pharmaceuticals, Inc | dfci.htm |
| EX-10.27 - EX-10.27 - X4 Pharmaceuticals, Inc | cadavidemploymentagreement.htm |
| EX-10.26 - EX-10.26 - X4 Pharmaceuticals, Inc | taveresemploymentagreement.htm |
| EX-4.12 - EX-4.12 - X4 Pharmaceuticals, Inc | descriptionofcommonstock.htm |
| 10-K - 10-K - X4 Pharmaceuticals, Inc | xfor-20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-229377, 333-233161, 333-242372 and 333-249544) and Form S-8 (Nos. 333-221622, 333-223539, 333-230181, 333-230499, 333-233162, 333-237164 and 333-239082) of X4 Pharmaceuticals, Inc. of our report dated March 19, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 19, 2021